The US market for Hemostats and Sealants dropped precipitously by -32.4% YoY in Q220, as the effects of COVD-19 became evident with many delayed or canceled surgeries.
With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Hemostats and Sealants market dropped -32.4% in Q220 according to SmartTRAK Financial Dashboard, a decrease that was presaged in Q120 earnings reports. Baxter* led the decline in Q220, down -42.1% YoY, with the Company’s sealants experiencing the worst YoY shrinkage. Cryolife* was close behind as its BioGlue* franchise saw cardiac surgeries postponed nationwide. In Q220, Ethicon* remained the market leader, followed by Baxter.
Among the many topics covered in the comprehensive Q220 US Hemostats and Sealants Market Recap* are:
- Complete US Hemostats and Sealants Market Overview
- Losses Dominate Biosurgery Market
- Absorbable Hemostats Suffer More Due To Pandemic
- Progel’s Relaunch Stalls
- Other Q220 events in the US Hemostats and Sealants Market
Though all manufacturers declined substantially in Q220, several manufacturers, such as Becton Dickinson* and Ethicon*, said there may be light at the end of the tunnel as their June biosurgery sales showed smaller declines than had been expected ...
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
